Ulipristal Acetate (Fibristal - Actavis Specialty Pharmaceuticals Co.) indication: uterine fibroids
CADTH
Record ID 32014000845
English
Authors' recommendations:
The Canadian Drug Expert Committee (CDEC) recommends that ulipristal acetate be listed for the treatment of moderate to severe signs and symptoms of uterine fibroids in adult women of reproductive age, who are eligible for surgery, if the following conditions are met:
1. The duration of treatment with ulipristal acetate should not exceed three months.
2.The patient is under the care of an obstetrician/gynecologist.
3.The drug plan costs for ulipristal acetate should not exceed the drug plan costs for the manufacturer's identified comparator, leuprolide acetate.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.cadth.ca/media/cdr/complete/complete_SR0326_Fibristal_19-Nov-13_e.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Humans
- Norpregnadienes
- Leiomyoma
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.